Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): The study protocol of a randomized placebo-controlled clinical trial (MILACLE study)

Yuji Ikeda, Yukari Uemura, Mikiko Asai-Sato, Takehiro Nakao, Takahiro Nakajima, Takashi Iwata, Azusa Akiyama, Toyomi Satoh, Hideaki Yahata, Kiyoko Kato, Daichi Maeda, Daisuke Aoki, Kei Kawana

Research output: Contribution to journalArticle

Abstract

We developed an HPV16 E7-expressing Lactobacillus-based therapeutic vaccine, IGMKK16E7, to elicit mucosal E7-specific TH1 cellular immune responses. This study aims to examine the safety and clinical efficacy of IGMKK16E7 on HPV16-positive high-grade squamous intraepithelial lesion (HSIL). This is a multicenter, placebo-controlled, double-blind randomized phase I/II trial to test the safety and efficacy of IGMKK16E7 against HPV16-positive HSIL. The groups will include placebo, low-dose (0.5 g/day), middle-dose (1 g/day), and high-dose (1.5 g/day) IGMKK16E7. The target sample size will be 41 patients per group, and our data on our former agent, GLBL101c, were used to calculate sample size for 70% power and an α level = 0.05. The primary endpoint is IGMKK16E7 safety and pathological regression at week 16, and the secondary endpoints are cytological regression and HPV16 E7 immunological response. This study protocol has been approved by the Japanese Pharmaceuticals and Medical Devices Agency. Patient enrollment will begin in May 2019.

Original languageEnglish
Pages (from-to)877-880
Number of pages4
JournalJapanese journal of clinical oncology
Volume49
Issue number9
DOIs
Publication statusPublished - Oct 15 2019

Fingerprint

Human papillomavirus 16
Lactobacillus
Immunotherapy
Vaccines
Randomized Controlled Trials
Placebos
Safety
Sample Size
Cellular Immunity
Therapeutics
Equipment and Supplies
Pharmaceutical Preparations
Squamous Intraepithelial Lesions of the Cervix

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL) : The study protocol of a randomized placebo-controlled clinical trial (MILACLE study). / Ikeda, Yuji; Uemura, Yukari; Asai-Sato, Mikiko; Nakao, Takehiro; Nakajima, Takahiro; Iwata, Takashi; Akiyama, Azusa; Satoh, Toyomi; Yahata, Hideaki; Kato, Kiyoko; Maeda, Daichi; Aoki, Daisuke; Kawana, Kei.

In: Japanese journal of clinical oncology, Vol. 49, No. 9, 15.10.2019, p. 877-880.

Research output: Contribution to journalArticle

Ikeda, Yuji ; Uemura, Yukari ; Asai-Sato, Mikiko ; Nakao, Takehiro ; Nakajima, Takahiro ; Iwata, Takashi ; Akiyama, Azusa ; Satoh, Toyomi ; Yahata, Hideaki ; Kato, Kiyoko ; Maeda, Daichi ; Aoki, Daisuke ; Kawana, Kei. / Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL) : The study protocol of a randomized placebo-controlled clinical trial (MILACLE study). In: Japanese journal of clinical oncology. 2019 ; Vol. 49, No. 9. pp. 877-880.
@article{75c95f33c7e14b53a2a24ae298094104,
title = "Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): The study protocol of a randomized placebo-controlled clinical trial (MILACLE study)",
abstract = "We developed an HPV16 E7-expressing Lactobacillus-based therapeutic vaccine, IGMKK16E7, to elicit mucosal E7-specific TH1 cellular immune responses. This study aims to examine the safety and clinical efficacy of IGMKK16E7 on HPV16-positive high-grade squamous intraepithelial lesion (HSIL). This is a multicenter, placebo-controlled, double-blind randomized phase I/II trial to test the safety and efficacy of IGMKK16E7 against HPV16-positive HSIL. The groups will include placebo, low-dose (0.5 g/day), middle-dose (1 g/day), and high-dose (1.5 g/day) IGMKK16E7. The target sample size will be 41 patients per group, and our data on our former agent, GLBL101c, were used to calculate sample size for 70{\%} power and an α level = 0.05. The primary endpoint is IGMKK16E7 safety and pathological regression at week 16, and the secondary endpoints are cytological regression and HPV16 E7 immunological response. This study protocol has been approved by the Japanese Pharmaceuticals and Medical Devices Agency. Patient enrollment will begin in May 2019.",
author = "Yuji Ikeda and Yukari Uemura and Mikiko Asai-Sato and Takehiro Nakao and Takahiro Nakajima and Takashi Iwata and Azusa Akiyama and Toyomi Satoh and Hideaki Yahata and Kiyoko Kato and Daichi Maeda and Daisuke Aoki and Kei Kawana",
year = "2019",
month = "10",
day = "15",
doi = "10.1093/jjco/hyz095",
language = "English",
volume = "49",
pages = "877--880",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL)

T2 - The study protocol of a randomized placebo-controlled clinical trial (MILACLE study)

AU - Ikeda, Yuji

AU - Uemura, Yukari

AU - Asai-Sato, Mikiko

AU - Nakao, Takehiro

AU - Nakajima, Takahiro

AU - Iwata, Takashi

AU - Akiyama, Azusa

AU - Satoh, Toyomi

AU - Yahata, Hideaki

AU - Kato, Kiyoko

AU - Maeda, Daichi

AU - Aoki, Daisuke

AU - Kawana, Kei

PY - 2019/10/15

Y1 - 2019/10/15

N2 - We developed an HPV16 E7-expressing Lactobacillus-based therapeutic vaccine, IGMKK16E7, to elicit mucosal E7-specific TH1 cellular immune responses. This study aims to examine the safety and clinical efficacy of IGMKK16E7 on HPV16-positive high-grade squamous intraepithelial lesion (HSIL). This is a multicenter, placebo-controlled, double-blind randomized phase I/II trial to test the safety and efficacy of IGMKK16E7 against HPV16-positive HSIL. The groups will include placebo, low-dose (0.5 g/day), middle-dose (1 g/day), and high-dose (1.5 g/day) IGMKK16E7. The target sample size will be 41 patients per group, and our data on our former agent, GLBL101c, were used to calculate sample size for 70% power and an α level = 0.05. The primary endpoint is IGMKK16E7 safety and pathological regression at week 16, and the secondary endpoints are cytological regression and HPV16 E7 immunological response. This study protocol has been approved by the Japanese Pharmaceuticals and Medical Devices Agency. Patient enrollment will begin in May 2019.

AB - We developed an HPV16 E7-expressing Lactobacillus-based therapeutic vaccine, IGMKK16E7, to elicit mucosal E7-specific TH1 cellular immune responses. This study aims to examine the safety and clinical efficacy of IGMKK16E7 on HPV16-positive high-grade squamous intraepithelial lesion (HSIL). This is a multicenter, placebo-controlled, double-blind randomized phase I/II trial to test the safety and efficacy of IGMKK16E7 against HPV16-positive HSIL. The groups will include placebo, low-dose (0.5 g/day), middle-dose (1 g/day), and high-dose (1.5 g/day) IGMKK16E7. The target sample size will be 41 patients per group, and our data on our former agent, GLBL101c, were used to calculate sample size for 70% power and an α level = 0.05. The primary endpoint is IGMKK16E7 safety and pathological regression at week 16, and the secondary endpoints are cytological regression and HPV16 E7 immunological response. This study protocol has been approved by the Japanese Pharmaceuticals and Medical Devices Agency. Patient enrollment will begin in May 2019.

UR - http://www.scopus.com/inward/record.url?scp=85073179935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073179935&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyz095

DO - 10.1093/jjco/hyz095

M3 - Article

C2 - 31613356

AN - SCOPUS:85073179935

VL - 49

SP - 877

EP - 880

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

ER -